AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31505943 — intervention group
Group type: COMPARATOR
Intervention: Flat insole (control)
Number of subjects: 72
Study 28158901 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 163
Study 28158901 — intervention group
Group type: COMPARATOR
Intervention: 180° anterior fundoplication
Number of subjects: 163
Study 26179504 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times per day for 3 days before surgery)
Number of subjects: 111
Study 26179504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times per day for 3 days before surgery)
Number of subjects: 111
Study 26179504 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 111
Study 26179504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 24281386 — intervention group
Group type: EXPERIMENTAL
Intervention: 7T SWI
Number of subjects: 10
Study 24281386 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T SWI
Number of subjects: 10
Study 21786271 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 44
Study 21786271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20814332 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (MPH)
Number of subjects: 223
Study 20814332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 17906207 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2 during 24 hours (arm 1)
Number of subjects: 140
Study 17906207 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 120 mg/m2 during 96 hours (arm 2)
Number of subjects: 140
Study 17906207 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 140
Study 16244050 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiving the 100-hour rule
Number of subjects: 0
Study 16244050 — intervention group
Group type: COMPARATOR
Intervention: 100-hour rule (control)
Number of subjects: 0
Study 11849578 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (H)
Number of subjects: 420
Study 11849578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (S)
Number of subjects: 420
Study 10094751 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure capnoperitoneum (15 mmHg)
Number of subjects: 20
Study 10094751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure capnoperitoneum (7 mmHg)
Number of subjects: 20
Study 8703860 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm treatment
Number of subjects: 100
Study 8703860 — intervention group
Group type: COMPARATOR
Intervention: 5 mm treatment
Number of subjects: 100
Study 8703860 — intervention group
Group type: COMPARATOR
Intervention: Multizone treatment
Number of subjects: 100
Study 1306051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (3 micrograms.kg‐1)
Number of subjects: 9
Study 1306051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.6 microgram.kg‐1)
Number of subjects: 9
Study 1306051 — intervention group
Group type: COMPARATOR
Intervention: Control (no opioid)
Number of subjects: 9
Study 6389559 — intervention group
Group type: EXPERIMENTAL
Intervention: Keller's operation modified by Kirschner‐wire distraction
Number of subjects: 0
Study 6389559 — intervention group
Group type: COMPARATOR
Intervention: Standard Keller's operation
Number of subjects: 0
Study 31686109 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant glycoprotein E herpes zoster vaccine
Number of subjects: 0
Study 31686109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30354701 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise (QE)
Number of subjects: 80
Study 30354701 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management (SM)
Number of subjects: 80
Study 30354701 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 26657263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection with betamethasone
Number of subjects: 74
Study 26657263 — intervention group
Group type: COMPARATOR
Intervention: Oral NSAIDs
Number of subjects: 74
Study 25000552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus fluocinolone acetonide
Number of subjects: 590
Study 25000552 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 590
Study 21508180 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 150 mg 3 times daily with quinidine 100 mg twice daily
Number of subjects: 102
Study 21508180 — intervention group
Group type: COMPARATOR
Intervention: Propafenone 150 mg 3 times daily with placebo
Number of subjects: 102
Study 19171275 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic iliopsoas tendon release at the lesser trochanter
Number of subjects: 19
Study 19171275 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic transcapsular psoas release from the peripheral compartment
Number of subjects: 19
Study 17048115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (5 Gm)
Number of subjects: 44
Study 17048115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (1.25 Gm or greater)
Number of subjects: 44
Study 17048115 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (control)
Number of subjects: 44
Study 15099876 — intervention group
Group type: EXPERIMENTAL
Intervention: filgrastim
Number of subjects: 40
Study 15099876 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 11943790 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood screening (FOB) for colorectal cancer
Number of subjects: 2184
Study 11943790 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety levels measured using the Spielberger anxiety inventory (SAI) in 100 test positive patients
Number of subjects: 2184
Study 12511809 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication (buspirone or fluoxetine)
Number of subjects: 113
Study 12511809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 12511809 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher predisposition toward action
Number of subjects: 113
Study 12511809 — intervention group
Group type: EXPERIMENTAL
Intervention: Precontemplation, contemplation, and maintenance scores
Number of subjects: 113
Study 12511809 — intervention group
Group type: EXPERIMENTAL
Intervention: Married or cohabiting status
Number of subjects: 113
Study 12511809 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness for action measure
Number of subjects: 113
Study 7622822 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 67
Study 7622822 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 67
Study 7622822 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) in placebo controlled trials
Number of subjects: 67
Study 7622822 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs) in placebo controlled trials
Number of subjects: 67
Study 2239377 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical technique exposing the conus medullaris through a T12-L1 laminectomy
Number of subjects: 10
Study 2239377 — intervention group
Group type: COMPARATOR
Intervention: Surgical technique exposing the dorsal roots distally in the cauda equina through a L2-L3 to S1 laminectomy
Number of subjects: 10
Study 379932 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole as adjunctive treatment between cycles of chemotherapy
Number of subjects: 60
Study 379932 — intervention group
Group type: COMPARATOR
Intervention: Conventional high dose chemotherapy
Number of subjects: 60
Study 31887090 — intervention group
Group type: EXPERIMENTAL
Intervention: AB‐ace (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with acepromazine [0.02 mg/kg])
Number of subjects: 6
Study 31887090 — intervention group
Group type: EXPERIMENTAL
Intervention: AB‐mid (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with midazolam [0.2 mg/kg])
Number of subjects: 6
Study 31887090 — intervention group
Group type: EXPERIMENTAL
Intervention: AB‐dex (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with dexmedetomidine [0.005 mg/kg])
Number of subjects: 6
Study 31438618 — intervention group
Group type: EXPERIMENTAL
Intervention: MegaSporeBiotic (Bacillus spp. spores) for 34 days
Number of subjects: 90
Study 31438618 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin for 10 days followed by nutraceutical agent (G1)
Number of subjects: 90
Study 31438618 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin for 10 days followed by low-FODMAP diet (G3)
Number of subjects: 90
Study 31438618 — intervention group
Group type: EXPERIMENTAL
Intervention: MegaSporeBiotic (Bacillus spp. spores)
Number of subjects: 90
Study 31438618 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin followed by nutraceutical or low-FODMAP diet
Number of subjects: 90
Study 28944901 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% mXCHD
Number of subjects: 30
Study 28944901 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mXCHD
Number of subjects: 30
Study 28944901 — intervention group
Group type: COMPARATOR
Intervention: entecavir
Number of subjects: 30
Study 28944901 — intervention group
Group type: COMPARATOR
Intervention: Healthy group
Number of subjects: 30
Study 25222572 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish aquarium animal‐assisted therapy (FA‐AAT)
Number of subjects: 69
Study 22609989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective nerve root block
Number of subjects: 120
Study 22609989 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided transforaminal block
Number of subjects: 120
Study 21316914 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarmed operating room at 24 °C
Number of subjects: 66
Study 21316914 — intervention group
Group type: COMPARATOR
Intervention: Control operating room at 17 °C
Number of subjects: 66
Study 19931151 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracaine
Number of subjects: 0
Study 19931151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16784341 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed with disliked outgroup (gay men)
Number of subjects: 0
Study 16784341 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed with 'elderly'
Number of subjects: 0
Study 16784341 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed with 'youth'
Number of subjects: 0
Study 16784341 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessibility of a primed category
Number of subjects: 0
Study 15085492 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa (Curosurf) 100 mg/kg
Number of subjects: 293
Study 15085492 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa (Curosurf) 200 mg/kg
Number of subjects: 293
Study 15085492 — intervention group
Group type: COMPARATOR
Intervention: Beractant (Survanta) 100 mg/kg
Number of subjects: 293
Study 11420324 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 16
Study 11420324 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg ketamine
Number of subjects: 16
Study 11420324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11420324 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 16
Study 10322818 — intervention group
Group type: EXPERIMENTAL
Intervention: IKPA tablets and inhalated BDP
Number of subjects: 57
Study 10322818 — intervention group
Group type: COMPARATOR
Intervention: Inhalated BDP singly
Number of subjects: 57
Study 8215734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (identified by predictive model)
Number of subjects: 60
Study 8215734 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (identified by predictive model)
Number of subjects: 60
Study 3469936 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate
Number of subjects: 144
Study 3469936 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular methotrexate
Number of subjects: 144
Study 29773516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoedema management package including instructions for foot hygiene, skin care, bandaging, exercises, and use of socks and shoes, supported by lay Community Podoconiosis Agents at monthly meetings.
Number of subjects: 696
Study 29773516 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 696
Study 27073044 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical liposomal azithromycin administered twice daily
Number of subjects: 66
Study 27073044 — intervention group
Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (glucantime) administered weekly with a volume of 0.5-2 cm3 into each lesion
Number of subjects: 66
Study 24186676 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate
Number of subjects: 53
Study 24186676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 22342850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy with aspirin and clopidogrel
Number of subjects: 632
Study 22342850 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with OAC, aspirin, and clopidogrel
Number of subjects: 632
Study 22342850 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC plus aspirin
Number of subjects: 632
Study 22342850 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC with either 1 or 2 antiplatelet agents
Number of subjects: 632
Study 22342850 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 632
Study 20039868 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia in conjunction with general anaesthesia
Number of subjects: 60
Study 20039868 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 60
Study 18578172 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaStyle Paint On Plus without VivaSens (Group A)
Number of subjects: 80
Study 18578172 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaStyle Paint On Plus after a single application of VivaSens (Group B)
Number of subjects: 80
Study 18578172 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but inferred as Group A)
Number of subjects: 80
Study 15290154 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate for Depot Suspension (3, 15 and 30 mg)
Number of subjects: 128
Study 11821495 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwarming biofeedback (HWB)
Number of subjects: 36
Study 11821495 — intervention group
Group type: COMPARATOR
Intervention: Handcooling (HCB)
Number of subjects: 36
Study 11821495 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 36
Study 10687569 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-chest position for 15 minutes three times a day for one week
Number of subjects: 100
Study 10687569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postural management)
Number of subjects: 100
Study 7492378 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for cure followed by postoperative chemotherapy (CAV - cyclophosphamide, doxorubicin, vincristine)
Number of subjects: 183
Study 2182696 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg sustained-release theophylline (morning and evening)
Number of subjects: 12
Study 2182696 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg sustained-release theophylline (two capsules morning and evening)
Number of subjects: 12
Study 2182696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules morning and evening)
Number of subjects: 12
Study 1096539 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT treatment
Number of subjects: 100
Study 1096539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT treatment
Number of subjects: 100
Study 1096539 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Unilateral and Bilateral)
Number of subjects: 100
Study 30475074 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback group (participants told their memory performance was better than peers)
Number of subjects: 203
Study 30475074 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral feedback group (participants told their memory performance was equivalent to peers)
Number of subjects: 203
Study 30475074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 203
Study 30969899 — intervention group
Group type: EXPERIMENTAL
Intervention: brief vibration during contraction
Number of subjects: 24
Study 30969899 — intervention group
Group type: EXPERIMENTAL
Intervention: prolonged vibration for 20 min before contraction
Number of subjects: 24
Study 30969899 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 24
Study 28482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (CT)
Number of subjects: 53454
Study 28482765 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray
Number of subjects: 53454
Study 25439114 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a dog during venipuncture (EG)
Number of subjects: 50
Study 25439114 — intervention group
Group type: COMPARATOR
Intervention: No dog present during venipuncture (CG)
Number of subjects: 50
Study 23039824 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dippers with normal awake and asleep SBP and DBP means
Number of subjects: 3344
Study 23039824 — intervention group
Group type: COMPARATOR
Intervention: Dippers with elevated ambulatory BP
Number of subjects: 3344
Study 23039824 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dippers with elevated ambulatory BP
Number of subjects: 3344
Study 22338468 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided antibiotic treatment (PCT-group; n = 102)
Number of subjects: 205
Study 22338468 — intervention group
Group type: COMPARATOR
Intervention: Standard care (standard group; n = 103)
Number of subjects: 205
Study 19444516 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (group A)
Number of subjects: 40
Study 19444516 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (group B)
Number of subjects: 40
Study 16682147 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression therapy (AST) administered at a PSA level of approximately 10 ng/mL
Number of subjects: 81
Study 14745141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atrial natriuretic peptide (ANP) administration
Number of subjects: 20
Study 14745141 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study 11401185 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in pharmacy practice-based research study
Number of subjects: 87
Study 11401185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy practice-based research
Number of subjects: 87
Study 11401185 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding pharmacists' opinions
Number of subjects: 87
Study 9244964 — intervention group
Group type: EXPERIMENTAL
Intervention: NeyTumorin
Number of subjects: 0
Study 7962387 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A: incubation of spermatozoa with pentoxifylline (PTX) and 2‐deoxyadenosine (DOA)
Number of subjects: 53
Study 7962387 — intervention group
Group type: COMPARATOR
Intervention: Method B: electroporation followed by incubation in medium with PTX
Number of subjects: 53
Study 7962387 — intervention group
Group type: COMPARATOR
Intervention: Method C: no further treatment with the Percoll gradient
Number of subjects: 53
Study 7962387 — intervention group
Group type: EXPERIMENTAL
Intervention: T6 medium containing 1.78 mM CaCl2.2H2O and final washing step in T6 medium containing 5.0 mM CaCl2.2H2O
Number of subjects: 53
Study 7962387 — intervention group
Group type: COMPARATOR
Intervention: Earle's medium containing 1.78 mM CaCl2.2H2O
Number of subjects: 53
Study 3297471 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.15 unit/kg body weight)
Number of subjects: 5
Study 3297471 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 5
Study 30625094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 130
Study 30625094 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive direct coronary artery bypass (MIDCAB)
Number of subjects: 130
Study 26809936 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 0
Study 26809936 — intervention group
Group type: COMPARATOR
Intervention: Race
Number of subjects: 0
Study 25710287 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg and PegIFN/RBV
Number of subjects: 308
Study 25710287 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg and PegIFN/RBV
Number of subjects: 308
Study 25710287 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of PegIFN/RBV
Number of subjects: 308
Study 25710287 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 weeks of PegIFN/RBV
Number of subjects: 308
Study 23676766 — intervention group
Group type: EXPERIMENTAL
Intervention: rESAT6
Number of subjects: 32
Study 23676766 — intervention group
Group type: COMPARATOR
Intervention: BSA
Number of subjects: 32
Study 23676766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 µg rESAT6
Number of subjects: 32
Study 23676766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 µg rESAT6
Number of subjects: 32
Study 23676766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg rESAT6
Number of subjects: 32
Study 20951320 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor administration in poor responders
Number of subjects: 826
Study 20951320 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor response to clopidogrel
Number of subjects: 826
Study 20951320 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor response to aspirin
Number of subjects: 826
Study 20951320 — intervention group
Group type: COMPARATOR
Intervention: Full responders
Number of subjects: 826
Study 18394495 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction
Number of subjects: 60
Study 18394495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 60